NASDAQ:KITE - (KITE) Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$179.79 As of 10/19/2017 01:00 AM ET

+0.30 (1.20%)

Get New (KITE) Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for KITE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KITE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for (KITE) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $179.79.

N/A

The current consensus among 0 investment analysts is to n/a stock in (KITE). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/22/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/21/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/19/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/17/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/16/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/16/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/15/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/14/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
8/29/2017	Wedbush	Upgrade	Underperform ➝ Neutral		Low	i Rating by D. Nierengarten at Wedbush
8/29/2017	Canaccord Genuity	Downgrade	Buy ➝ Hold		Low	i Rating by John Newman at Canaccord Genuity
8/28/2017	Guggenheim	Downgrade	Buy ➝ Neutral	$128.00	Low	i
8/28/2017	SunTrust Banks	Downgrade	Buy ➝ Hold		Medium	i
8/28/2017	BTIG Research	Downgrade	Buy ➝ Neutral		High	i
8/10/2017	Stifel Nicolaus	Reiterated Rating	Hold	$74.00	Low	i
8/9/2017	Jefferies Financial Group	Reiterated Rating	Buy	$121.00 ➝ $135.00	Low	i Rating by Biren Amin at Jefferies Financial Group Inc.
8/9/2017	Canaccord Genuity	Set Price Target	Buy	$115.00 ➝ $120.00	Medium	i Rating by John Newman at Canaccord Genuity
7/13/2017	Maxim Group	Downgrade	Buy ➝ Hold	$88.00	Low	i Rating by Jason McCarthy at Maxim Group
7/10/2017	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$101.00 ➝ $121.00	Medium	i Rating by Biren Amin at Jefferies Financial Group Inc.
7/10/2017	Canaccord Genuity	Set Price Target	Buy	$115.00	Medium	i Rating by John Newman at Canaccord Genuity
7/4/2017	Roth Capital	Reiterated Rating	Buy	$93.00	Medium	i Rating by Mark Breidenbach at Roth Capital
7/4/2017	Cowen	Reiterated Rating	Outperform		Medium	i
6/27/2017	Canaccord Genuity	Set Price Target	Buy	$115.00	N/A	i Rating by John Newman at Canaccord Genuity
6/26/2017	Cowen	Reiterated Rating	Outperform		Medium	i
6/26/2017	Jefferies Financial Group	Reiterated Rating	Buy	$101.00	Medium	i Rating by Biren Amin at Jefferies Financial Group Inc.
6/16/2017	Wedbush	Reiterated Rating	Underperform	$54.00	Low	i Rating by D. Nierengarten at Wedbush
6/9/2017	Jefferies Financial Group	Reiterated Rating	Buy	$101.00	Low	i Rating by Biren Amin at Jefferies Financial Group Inc.
6/8/2017	BTIG Research	Upgrade	Neutral ➝ Buy	$100.00	High	i
6/7/2017	Cowen	Reiterated Rating	Buy		High	i
6/6/2017	Canaccord Genuity	Set Price Target	Buy	$90.00	High	i Rating by John Newman at Canaccord Genuity
5/30/2017	(FBRC)	Reiterated Rating	Buy		Low	i Rating by Edward White at (FBRC)
5/19/2017	Jefferies Financial Group	Set Price Target	Buy	$101.00	Medium	i Rating by Biren Amin at Jefferies Financial Group Inc.
5/19/2017	HC Wainwright	Reiterated Rating	Buy	$85.00	Medium	i Rating by Corey Davis at HC Wainwright
5/19/2017	BTIG Research	Reiterated Rating	Neutral		Medium	i
5/15/2017	Raymond James	Downgrade	Outperform ➝ Mkt Perform		N/A	i
5/9/2017	Maxim Group	Set Price Target	Buy	$88.00	High	i Rating by Jason McCarthy at Maxim Group
5/9/2017	Wedbush	Downgrade	Neutral ➝ Underperform	$60.00 ➝ $54.00	High	i Rating by D. Nierengarten at Wedbush
5/9/2017	The Goldman Sachs Group	Boost Price Target	Buy	$85.00 ➝ $89.00	High	i
5/9/2017	Cowen	Reiterated Rating	Neutral	$74.00	High	i
5/9/2017	Canaccord Genuity	Reiterated Rating	Buy	$90.00	High	i Rating by John Newman at Canaccord Genuity
5/9/2017	(FBRC)	Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $91.00	Medium	i Rating by Edward White at (FBRC)
5/8/2017	Raymond James	Reiterated Rating	Outperform ➝ Mkt Perform		High	i
5/8/2017	UBS Group	Downgrade	Outperform ➝ Market Perform		N/A	i
4/20/2017	Canaccord Genuity	Set Price Target	Buy	$90.00	Low	i Rating by John Newman at Canaccord Genuity
4/20/2017	Jefferies Financial Group	Reiterated Rating	Buy		Medium	i Rating by Biren Amin at Jefferies Financial Group Inc.
4/6/2017	Roth Capital	Reiterated Rating	Buy	$93.00	High	i Rating by Mark Breidenbach at Roth Capital
4/6/2017	Cowen	Reiterated Rating	Outperform		High	i
4/3/2017	Canaccord Genuity	Reiterated Rating	Buy	$90.00	High	i Rating by John Newman at Canaccord Genuity
4/3/2017	Maxim Group	Set Price Target	Buy	$84.00 ➝ $100.00	High	i Rating by Jason McCarthy at Maxim Group
4/3/2017	Jefferies Financial Group	Reiterated Rating	Buy	$101.00	High	i Rating by Biren Amin at Jefferies Financial Group Inc.
4/3/2017	Wedbush	Reiterated Rating	Neutral	$60.00	High	i Rating by D. Nierengarten at Wedbush
3/30/2017	BTIG Research	Reiterated Rating	Hold		Low	i
3/20/2017	Roth Capital	Set Price Target	Buy	$93.00	High	i Rating by Mark Breidenbach at Roth Capital
3/16/2017	Jefferies Financial Group	Reiterated Rating	Buy	$82.00 ➝ $101.00	Low	i Rating by Biren Amin at Jefferies Financial Group Inc.
3/15/2017	Canaccord Genuity	Reiterated Rating	Buy	$75.00 ➝ $90.00	Low	i Rating by John Newman at Canaccord Genuity
3/13/2017	Standpoint Research	Downgrade	Buy ➝ Hold	$85.00	Low	i
3/11/2017	Maxim Group	Reiterated Rating	Buy	$84.00	N/A	i Rating by Jason McCarthy at Maxim Group
3/7/2017	Cowen	Reiterated Rating	Outperform		N/A	i
3/6/2017	Royal Bank of Canada	Boost Price Target	Outperform	$85.00 ➝ $95.00	N/A	i Rating by Michael Yee at Royal Bank of Canada
3/6/2017	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$85.00 ➝ $95.00	N/A	i
3/3/2017	BTIG Research	Reiterated Rating	Neutral		N/A	i
3/3/2017	Wedbush	Reiterated Rating	Neutral	$46.00 ➝ $60.00	N/A	i Rating by D. Nierengarten at Wedbush
3/3/2017	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$74.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
3/2/2017	Citigroup	Downgrade	Buy ➝ Neutral	$62.00 ➝ $87.00	N/A	i
3/1/2017	Maxim Group	Boost Price Target	Buy ➝ Buy	$77.00 ➝ $84.00	N/A	i Rating by Jason McCarthy at Maxim Group
2/28/2017	Roth Capital	Set Price Target	Buy	$83.00	N/A	i Rating by Mark Breidenbach at Roth Capital
2/28/2017	Canaccord Genuity	Set Price Target	Buy	$75.00	N/A	i Rating by John Newman at Canaccord Genuity
2/28/2017	HC Wainwright	Set Price Target	Buy ➝ Buy	$78.00 ➝ $85.00	N/A	i Rating by Corey Davis at HC Wainwright
2/28/2017	Standpoint Research	Reiterated Rating	Buy ➝ Buy	$85.00	N/A	i
2/27/2017	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
2/22/2017	HC Wainwright	Reiterated Rating	Buy	$78.00 ➝ $85.00	N/A	i Rating by Corey Davis at HC Wainwright
2/22/2017	Wells Fargo & Company	Initiated Coverage	Market Perform ➝ Market Perform		N/A	i
2/1/2017	Wedbush	Initiated Coverage	Neutral	$46.00	N/A	i Rating by D. Nierengarten at Wedbush
1/24/2017	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i
1/17/2017	Maxim Group	Reiterated Rating	Buy	$77.00	N/A	i Rating by Jason McCarthy at Maxim Group
1/8/2017	(FBRC)	Set Price Target	Buy	$78.00	N/A	i Rating by Edward White at (FBRC)
1/4/2017	Roth Capital	Initiated Coverage	Buy	$68.00	N/A	i Rating by M. Breidenbach at Roth Capital
12/12/2016	Stifel Nicolaus	Reiterated Rating	Buy		N/A	i Rating by Thomas Shrader at Stifel Nicolaus
12/9/2016	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
12/7/2016	HC Wainwright	Reiterated Rating	Buy	$78.00	N/A	i Rating by Corey Davis at HC Wainwright
12/6/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
12/5/2016	Maxim Group	Set Price Target	Buy	$77.00	N/A	i Rating by Jason McCarthy at Maxim Group
12/5/2016	Stifel Nicolaus	Reiterated Rating	Buy	$74.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
11/29/2016	Canaccord Genuity	Set Price Target	Buy	$75.00	N/A	i Rating by John Newman at Canaccord Genuity
11/26/2016	Stifel Nicolaus	Reiterated Rating	Buy	$74.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
11/24/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by Michael Yee at Royal Bank of Canada
11/23/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
11/22/2016	BTIG Research	Reiterated Rating	Hold		N/A	i
11/21/2016	HC Wainwright	Initiated Coverage	Buy	$78.00	N/A	i
11/13/2016	BTIG Research	Reiterated Rating	Hold		N/A	i
11/10/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
11/1/2016	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
10/19/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
10/19/2016	Maxim Group	Set Price Target	Buy	$77.00	N/A	i Rating by Jason McCarthy at Maxim Group
10/19/2016	Canaccord Genuity	Set Price Target	Buy	$75.00	N/A	i Rating by John Newman at Canaccord Genuity
10/18/2016	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
10/10/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$70.00	N/A	i
10/9/2016	BTIG Research	Reiterated Rating	Neutral		N/A	i
10/7/2016	Canaccord Genuity	Reiterated Rating	Buy	$75.00	N/A	i Rating by John Newman at Canaccord Genuity
10/6/2016	Maxim Group	Set Price Target	Buy	$77.00	N/A	i Rating by Jason McCarthy at Maxim Group
10/6/2016	Stifel Nicolaus	Set Price Target	Buy	$74.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
9/30/2016	Stifel Nicolaus	Reiterated Rating	Buy	$74.00	N/A	i Rating by thomas shrader at Stifel Nicolaus
9/27/2016	(FBRC)	Reiterated Rating	Outperform	$78.00	N/A	i Rating by Edward White at (FBRC)
9/27/2016	BTIG Research	Reiterated Rating	Neutral		N/A	i
9/27/2016	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
9/27/2016	Barclays	Boost Price Target	Equal Weight	$60.00 ➝ $65.00	N/A	i Rating by jonathan eckard at Barclays PLC
9/22/2016	Stifel Nicolaus	Reiterated Rating	Buy	$74.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
9/19/2016	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
8/30/2016	BTIG Research	Initiated Coverage	Neutral		N/A	i
8/9/2016	Mizuho	Set Price Target	Buy	$80.00	N/A	i Rating by eric criscuolo at Mizuho
8/9/2016	Barclays	Set Price Target	Hold	$58.00 ➝ $60.00	N/A	i
8/9/2016	Maxim Group	Reiterated Rating	Buy	$87.00 ➝ $77.00	N/A	i Rating by Jason McCarthy at Maxim Group
8/5/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
7/26/2016	Canaccord Genuity	Reiterated Rating	Buy	$75.00	N/A	i Rating by John Newman at Canaccord Genuity
7/22/2016	Mizuho	Reiterated Rating	Buy	$80.00	N/A	i Rating by Eric Criscuolo at Mizuho
7/15/2016	Mizuho	Reiterated Rating	Buy	$80.00	N/A	i Rating by Eric Criscuolo at Mizuho
7/13/2016	Canaccord Genuity	Reiterated Rating	Buy	$75.00	N/A	i Rating by John Newman at Canaccord Genuity
7/13/2016	Stifel Nicolaus	Boost Price Target	Hold ➝ Buy	$63.00 ➝ $74.00	N/A	i Rating by Thomas Shrader at Stifel Nicolaus
7/10/2016	(FBRC)	Reiterated Rating	Outperform	$75.00	N/A	i Rating by Edward White at (FBRC)
7/9/2016	Jefferies Financial Group	Reiterated Rating	Buy	$72.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
7/8/2016	Mizuho	Reiterated Rating	Hold	$80.00	N/A	i Rating by Eric Criscuolo at Mizuho
7/6/2016	Barclays	Initiated Coverage	Equal Weight	$58.00	N/A	i
6/20/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc

(Data available from 6/14/2016 forward)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Today's Range

Now: $179.79

$179.79

50 Day Range

MA: N/A

52 Week Range

Now: $179.79

$39.82

$179.99

Volume

N/A

Average Volume

1,652,408 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (KITE)?

The following Wall Street analysts have issued reports on (KITE) in the last year:
View the latest analyst ratings for KITE.

What is the current price target for (KITE)?

0 Wall Street analysts have set twelve-month price targets for (KITE) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (KITE) in the next year.
View the latest price targets for KITE.

What is the current consensus analyst rating for (KITE)?

(KITE) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KITE.

How do I contact (KITE)'s investor relations team?

(KITE)'s physical mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company's listed phone number is +1-310-8249999. The official website for (KITE) is www.kitepharma.com.